Episode 140: Turning Opioid Clinical Decisions Into Crimes With Jay Joshi

Episode 140: Turning Opioid Clinical Decisions Into Crimes With Jay Joshi

Dr. Jay Joshi, a physician, entrepreneur, and author of the book “Burden of Pain: A Physician’s Journey through the Opioid Epidemic,” joins the show to share his story of how he was indicted for what was perceived as over-prescribing opioids and narcotics. He explains his unique model of primary care delivery he established, the experience of being arrested by the DEA for his practices, and the chain of events leading to indictment, plea bargaining, and a prison sentence. Dr. Joshi’s story is a snapshot of the intense twists and turns of the opioid epidemic and legal system that followed.

Related Resources

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More